Opus Genetics, Inc. Common Stock

IRD XNAS • PHARMACEUTICAL PREPARATIONS

Historical Short Interest Share

American Express® Business Gold Card

Earn Up to 200K Membership Rewards® Points

4X on your top 2 spending categories. Transfer to 20+ airline & hotel partners. Terms apply.

Learn More

Market Cap

320M

Short interest (May 15)

3.8%

Net Short (Jun 03 ): 0.1%

Borrow Fee

0.79%

↓ 1.5%

Available Shares

↑ 50.7%

Price Chart

Company Overview

Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline includes seven adeno-associated virus (AAV)-based programs, led by OPGx-LCA5 for LCA5-related mutations and OPGx-BEST1 for BEST1-related retinal degeneration, with additional candidates targeting RHO, CNGB1, RDH12, NMNAT1, and MERTK. The company operates in one operating segment, which is the business of developing products related to vision performance and health.

Company Info

Exchange: NASDAQ

Industry: PHARMACEUTICAL PREPARATIONS

CIK: 0001228627

Asset Type: CS

Market Data

Market Cap: $324,768,200

Employees: 28

Status: Active

Short Interest

Current Borrow Fee 0.79%

Range: 0.45% - 0.85%

Available Shares 3M

Range: 2.4M - 2.8M

Recent Changes

Fee Change: ↑ 25.8%

Available Change: ↑ 10.0%

Quick Actions

View Dilution Chart

Add to Watchlist Set Price Alert View Options Chain

Investment Risk

This is not financial advice. All investments carry risk. Do your own research before making investment decisions.

Weekly Research

Get Weekly Super Stonk Alerts

Never miss a squeeze opportunity. Get our weekly analysis of high short interest stocks, AI-discovered gems, and dilution warnings delivered to your inbox.

No spam • Unsubscribe anytime